Our customer services representatives are available 24 hours a day, from Monday to Sunday.
CONTACT USVirus-like particles (VLPs) are nanoscale structures that replicate the external architecture of viruses while lacking any genetic material, allowing them to elicit robust immune responses without infection risk. Their particulate nature and dense, repetitive display of epitopes promote effective recognition by the immune system, which can reduce dependence on adjuvants in vaccine formulations.
VLPs can be expressed in various systems depending on desired post-translational modifications, scalability, and cost considerations:
VLP production begins with cell expansion and induction of viral protein expression. Depending on whether VLPs are secreted or intracellular, recovery may involve direct harvesting or controlled cell lysis. Optimizing these strategies can influence yield, downstream purification efficiency, and product quality. Process monitoring, including cell viability and expression kinetics, is essential to maintain consistency and reproducibility.
Post-harvest, cells and debris are removed using tangential flow filtration, depth filtration, or centrifugation. Process parameters are adjusted to minimize loss of particles while efficiently reducing host cell proteins and aggregates, preparing the product for downstream purification.
Residual host DNA is fragmented using recombinant endonucleases under defined conditions and subsequently cleared through filtration or chromatographic methods, ensuring compliance with regulatory standards for DNA content. Optimization of enzyme incubation and buffer conditions is critical for consistent DNA reduction.
Purification focuses on achieving high purity while maintaining VLP integrity. Typical steps include:
Formulations often contain buffers, sugars, and surfactants to preserve particle stability. Additional excipients adjust pH, osmolarity, and long-term storage properties. Sterile filtration and controlled filling ensure product safety and quality. Advanced formulation strategies, including lyophilization or liquid stabilization, can further extend shelf life and maintain immunogenicity.
VLPs offer strong immunogenicity while maintaining favorable safety profiles. Choice of expression system, scale-up feasibility, purification strategy, and formulation stability are critical to producing high-quality vaccines. Integrating these factors ensures both effective immune response and regulatory compliance. Continuous process optimization and quality monitoring are essential to meet evolving standards and support accelerated vaccine development.
As a trusted partner in vaccine innovation, Alfa Chemistry provides comprehensive support for VLP-based vaccine research, process optimization, and formulation solutions, helping accelerate the journey from laboratory concept to scalable, reliable vaccine production while ensuring product quality and consistency.
Our products and services are for research use only and cannot be used for any clinical purposes.
Alfa Chemistry is a global leader in the vaccine industry. We have the ability to help our customers meet the challenges of various vaccine development processes. Alfa Chemistry believes that partnerships will change the way the world innovates, bringing new technologies.
Interested in our Services & Products? Need detailed information?
Privacy Policy | Cookie Policy | Copyright © 2026 Alfa Chemistry. All rights reserved.